Human monoclonal antibodies against interleukin 8 (IL-8)
AssigneeGenmab A/S
InventorsJessica Teeling, Paul Parren, Ole Baadsgaard, Debra Hudson, Jørgen Petersen
Life of this patent
Estimating the term…
Abstract
Isolated human monoclonal antibodies which bind to IL-8 (e.g., human IL-8) are disclosed. The human antibodies can be produced in a hybridoma, transfectoma or in a non-human transgenic animal, e.g., a transgenic mouse, capable of producing multiple isotypes of human monoclonal antibodies by undergoing V-D-J recombination and isotype switching. Also disclosed are pharmaceutical compositions comprising the human antibodies, non-human transgenic animals, hybridomas, and transfectomas which produce the human antibodies, and therapeutic and diagnostic methods for using the human antibodies.
Claims15
An isolated monoclonal antibody which binds to human IL-8, wherein the antibody comprises a heavy chain variable region comprising the amino acid sequence set forth in SEQ ID NO:
- 12 or encoded by the nucleotide sequence set forth in SEQ ID NO:10.
An isolated monoclonal antibody which binds to human IL-8, wherein the antibody comprises a light chain variable region comprising the amino acid sequence set forth in SEQ ID NO:8 or encoded by the nucleotide sequence set forth in SEQ ID NO:6.
An isolated monoclonal antibody which binds an epitope on human IL-8 recognized by an antibody comprising heavy and light chain variable regions comprising the amino acid sequences set forth in SEQ ID NOs:12 and 8, respectively.
An isolated monoclonal antibody which binds to human IL-8, wherein the antibody comprises heavy and light chain variable regions comprising CDR1, CDR2, and CDR3 sequences, wherein the heavy and light chain variable region CDR2 sequences comprise the amino acid sequences set forth in SEO ID NOs:23 and 17, respectively, the heavy and light chain variable region CDR1 sequences comprise the amino acid sequences set forth in SEO ID NOs:22 and 16, respectively, and wherein
- the heavy chain CDR3 sequence comprises the amino acid sequence set forth in SEQ TD NO:24 or the amino acid sequence Asp-X4-Val-Gly-X5-Phe-Asp-Tyr (SEQ ID NO:
- 47), wherein X4 is Lys, Arg, or His, and X5 is Gly, Ala, Val, Leu, or Ile, and
- the light chain variable region CDR3 sequence comprises the amino acid sequence set forth in SEQ ID NO:18 or the amino acid sequence Gln-Gln-Tyr-X1-X2-Ser-X3-Thr (SEQ ID NO:
- 46), wherein X1, X2 and X3 each represents a natural amino acid residue, and X1 is different from Gly, or X2 is different from Ser, or X3 is different from Pro.
Dependencies are inferred from the claim text.